Results for tag: "E3 Ligase Ligands"

The E3 Ligase Ligands market within the Pharmaceuticals industry is a rapidly growing sector. It is a class of drugs that target the ubiquitin-proteasome system, which is responsible for the degradation of proteins in cells. These drugs are used to treat a variety of diseases, including cancer, autoimmune diseases, and neurological disorders. They are also used to modulate the activity of certain proteins, such as transcription factors, to regulate gene expression. E3 Ligase Ligands are typically small molecules that bind to the E3 ubiquitin ligase, which is responsible for the ubiquitination of proteins. This process marks the proteins for degradation by the proteasome. By targeting the E3 ubiquitin ligase, these drugs can modulate the activity of certain proteins, leading to therapeutic effects. Some of the major companies in the E3 Ligase Ligands market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more